Compare GRND & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRND | DFTX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | 148 | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | GRND | DFTX |
|---|---|---|
| Price | $12.27 | $20.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $19.67 | ★ $40.25 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $17.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.79 | $14.62 |
| 52 Week High | $25.13 | $21.10 |
| Indicator | GRND | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 63.40 |
| Support Level | $11.83 | $16.41 |
| Resistance Level | $12.90 | N/A |
| Average True Range (ATR) | 0.46 | 1.09 |
| MACD | -0.07 | 0.23 |
| Stochastic Oscillator | 39.19 | 82.97 |
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).